Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenofovir alafenamide in chronic hepatitis B with or without nonalcoholic fatty liver disease
ChiCTR1900023153Phase 4Not yet recruiting
- Sponsor
- Jinyu Xia
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tenofovir alafenamide in Chronic Hepatitis B (CHB) (2 arms), sponsored by Jinyu Xia. Primary endpoints: HBV DNA inhibition rate, Renal function and 1 more. Planned start Mar 2019; status: not yet recruiting.
02
Drugs
tenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR1900023153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023153.